- Home
- USCB vs CAPR Comparison
USCB vs CAPR Comparison
Compare USCB & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- CAPR
- Stock Information
- Founded
- USCB 2002
- CAPR 2005
- Country
- USCB United States
- CAPR United States
- Employees
- USCB N/A
- CAPR N/A
- Industry
- USCB Major Banks
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USCB Finance
- CAPR Health Care
- Exchange
- USCB Nasdaq
- CAPR Nasdaq
- Market Cap
- USCB 316.4M
- CAPR 324.6M
- IPO Year
- USCB 2021
- CAPR N/A
- Fundamental
- Price
- USCB $17.34
- CAPR $6.28
- Analyst Decision
- USCB Buy
- CAPR Strong Buy
- Analyst Count
- USCB 3
- CAPR 8
- Target Price
- USCB $20.33
- CAPR $24.75
- AVG Volume (30 Days)
- USCB 16.8K
- CAPR 1.4M
- Earning Date
- USCB 07-24-2025
- CAPR 08-11-2025
- Dividend Yield
- USCB 2.30%
- CAPR N/A
- EPS Growth
- USCB 67.08
- CAPR N/A
- EPS
- USCB 1.47
- CAPR N/A
- Revenue
- USCB $88,094,000.00
- CAPR $13,392,150.00
- Revenue This Year
- USCB $26.38
- CAPR N/A
- Revenue Next Year
- USCB $4.39
- CAPR $6,061.53
- P/E Ratio
- USCB $11.83
- CAPR N/A
- Revenue Growth
- USCB 32.06
- CAPR N/A
- 52 Week Low
- USCB $13.85
- CAPR $3.98
- 52 Week High
- USCB $21.86
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- USCB 55.15
- CAPR 36.33
- Support Level
- USCB $17.10
- CAPR $6.17
- Resistance Level
- USCB $17.98
- CAPR $7.30
- Average True Range (ATR)
- USCB 0.52
- CAPR 0.43
- MACD
- USCB 0.06
- CAPR -0.11
- Stochastic Oscillator
- USCB 73.38
- CAPR 4.53
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.